Vaxzevria COVID-19 vaccine
E505486
Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Vaxzevria COVID-19 vaccine canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T5248768 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Vaxzevria COVID-19 vaccine Context triple: [AstraZeneca, developedProduct, Vaxzevria COVID-19 vaccine]
-
A.
Janssen COVID-19 Vaccine
The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
-
B.
Sinovac
Sinovac is a Chinese biopharmaceutical company best known globally for developing the inactivated COVID-19 vaccine CoronaVac.
-
C.
Moderna
Moderna is a biotechnology company best known for pioneering mRNA-based vaccines, including one of the first widely used COVID-19 vaccines.
-
D.
Pfizer–BioNTech
Pfizer–BioNTech is a pharmaceutical partnership best known for developing one of the first widely authorized mRNA vaccines against COVID-19.
-
E.
COVID-19 vaccines
COVID-19 vaccines are immunizations developed to protect against the SARS-CoV-2 virus, significantly reducing the risk of severe illness, hospitalization, and death from COVID-19.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Vaxzevria COVID-19 vaccine Target entity description: Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
-
A.
Janssen COVID-19 Vaccine
The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
-
B.
Sinovac
Sinovac is a Chinese biopharmaceutical company best known globally for developing the inactivated COVID-19 vaccine CoronaVac.
-
C.
Moderna
Moderna is a biotechnology company best known for pioneering mRNA-based vaccines, including one of the first widely used COVID-19 vaccines.
-
D.
Pfizer–BioNTech
Pfizer–BioNTech is a pharmaceutical partnership best known for developing one of the first widely authorized mRNA vaccines against COVID-19.
-
E.
COVID-19 vaccines
COVID-19 vaccines are immunizations developed to protect against the SARS-CoV-2 virus, significantly reducing the risk of severe illness, hospitalization, and death from COVID-19.
- F. None of above. chosen
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
COVID-19 vaccine
ⓘ
pharmaceutical product ⓘ |
| belongsToCategory |
SARS-CoV-2 vaccines
ⓘ
adenoviral vector vaccines ⓘ |
| doesNotContain |
live SARS-CoV-2 virus
ⓘ
mRNA ⓘ |
| doseInterval | 4 to 12 weeks ⓘ |
| encodesAntigen | SARS-CoV-2 spike protein ⓘ |
| hasActiveIngredient | ChAdOx1-S NERFINISHED ⓘ |
| hasAdverseEvent |
anaphylaxis
ⓘ
blood clotting disorders ⓘ thrombosis with thrombocytopenia syndrome ⓘ |
| hasAlternativeName |
AZD1222
NERFINISHED
ⓘ
AstraZeneca COVID-19 vaccine NERFINISHED ⓘ ChAdOx1 nCoV-19 NERFINISHED ⓘ Oxford–AstraZeneca COVID-19 vaccine NERFINISHED ⓘ |
| hasClinicalTrialPhase | Phase III completed ⓘ |
| hasCommonSideEffect |
chills
ⓘ
fatigue ⓘ fever ⓘ headache ⓘ injection site pain ⓘ muscle pain ⓘ |
| hasDeveloper |
AstraZeneca
NERFINISHED
ⓘ
University of Oxford NERFINISHED ⓘ |
| hasEfficacy |
high protection against severe COVID-19
ⓘ
reduced risk of symptomatic COVID-19 ⓘ |
| hasManufacturer | AstraZeneca plc NERFINISHED ⓘ |
| hasRegulatoryApproval |
European Medicines Agency
NERFINISHED
ⓘ
World Health Organization Emergency Use Listing NERFINISHED ⓘ |
| hasRegulatoryStatusChange | suspended or restricted in some countries ⓘ |
| hasVaccinePlatform | non-replicating viral vector ⓘ |
| indicatedForAgeGroup |
18 years and older
ⓘ
adults ⓘ |
| isGeneticMaterialType | DNA ⓘ |
| isNonReplicating | true ⓘ |
| prevents |
COVID-19-related death
ⓘ
COVID-19-related hospitalization ⓘ SARS-CoV-2 infection ⓘ severe COVID-19 ⓘ |
| routeOfAdministration | intramuscular injection ⓘ |
| storageTemperature | refrigerated 2–8 °C ⓘ |
| targetsDisease | COVID-19 NERFINISHED ⓘ |
| typicalDoseCount | 2 doses ⓘ |
| usesVector | chimpanzee adenovirus ⓘ |
| wasFirstUsedIn | 2020 ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Vaxzevria COVID-19 vaccine Description of subject: Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.